Erik Musiek, MD, PhD
Dr. Musiek sees patients with cognitive disorders in Memory Disorder Clinic, participates in clinical studies through the Knight Alzheimer’s Disease Research Center (KADRC), and performs laboratory research on the molecular basis of age-related neurodegenerative diseases, particularly Alzheimer’s Disease, using animal and cellular models.
Dr. Musiek graduated summa cum laude from the College of William and Mary with a B.S. in Biological Psychology in 1999, and was elected to Phi Beta Kappa. He entered the Medical Scientist Training Program at Vanderbilt University School of Medicine in 2000, and received his Ph.D. in Pharmacology in 2005 and his M.D. in 2007. His thesis work in the labs of Drs. Jason Morrow and BethAnn McLaughlin examined the role of novel lipid peroxidation products in neuroinflammation and neurodegeneration. At Vanderbilt, he was elected to Alpha Omega Alpha and received the Kampmeier Prize in Medicine. He completed his internship in Internal Medicine at Vanderbilt, then residency in Neurology at the University of Pennsylvania in 2011. While at PENN, he pursued research in the lab of Dr. Garret FitzGerald and received the Samuel Zeritsky Outstanding Resident Research Award. He came to Washington University in 2011 as a Postdoctoral Fellow in the Knight Alzheimer’s Disease Research Center (ADRC) under the mentorship of Drs. John Morris and David Holtzman. He was awarded an NIH K08 Physician Scientist training grant in 2012 with Dr. Holtzman as mentor.
Dr. Musiek’s research interests focus on the molecular mechanisms of neurodegeneration, with a special interest in oxidative stress. A major focus is the role of circadian clock genes in the regulation of brain oxidative stress, bioenergetics, and neurodegeneration. A second project examines how certain proteins which are associated with neurodegenerative disease, such as Apolipoprotein E, modulate oxidative stress responses in the brain. Ongoing studies in humans seek to understand the phenotypic and biochemical similarities between autosomal dominant (familial) and sporadic Alzheimer’s Disease, as well as to employ mass spectrometry and PET-based amyloid imaging techniques to elucidate the relationship between brain amyloid deposition, neuronal oxidative damage, and dementia in living patients.
Musiek ESand Holtzman DH (2012) Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement. Curr Opin Neurol., 25; 715-20.
Musiek ES, Chen Y, Korczykowski M, Saboury B, Martinez PM, Reddin JS, Alavi A, Newberg AB, Julin P, Arnold SE, Detre JA (2011) Direct Comparison of FDG-PET and ASL-MRI in Alzheimer’s Disease. Alzheimers Dement, 8; 51-9.
Chen Y, Wolk DA, Reddin JS, Korczykowski M, Martinez PM,Musiek ES, Newberg AB, Julin P, Arnold SE, Greenberg JH, Detre JA (2011) Voxel level Comparison Of Arterial Spin Labeled Perfusion MRI And FDG-PET In Alzheimer’s Disease. Neurology, 77; 1977-85.
Musiek ES, Brooks JD, Joo M, Brunoldi E, Porta A, Zanoni G, Vidari G, Blackwell TS, Montine TJ, Milne GL, McLaughlin B, Morrow JD (2008) Electrophilic cyclopentenone neuroprostanes are anti-inflammatory mediators formed from the peroxidation of the omega-3 polyunsaturated fatty acid docosahexaenoic acid. J. Biol. Chem., 283: 19927-35.
Musiek ES, Milne GL, Everhart MB, Wang, D, Backlund MG, DuBois RN, Blackwell TN, Vidari G, Zanoni G, Morrow JD (2005) Cyclopentenone isoprostanes inhibit the inflammatory response in macrophages. J. Biol. Chem., 280; 35562-70
Musiek ES, Breeding RS, Milne GL, Morrow JD, McLaughlin B (2006). Cyclopentenone isoprostanes are novel products of lipid oxidation which enhance neurodegeneration. J. Neurochem., 97; 1301-13.
Milne GL, Sanchez SC,Musiek ES, Morrow JD (2007). Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nature Protocols, 2; 221-6
Brown JE, Zeiger SL, Hettinger JC, Brooks JD, Holt B, Morrow JD,Musiek ES, Milne G, and McLaughlin B (2010) Essential Role of the Redox Sensitive Kinase p66shc in Determining Energetic and Oxidative Status and Cell Fate in Neuronal Preconditioning. J. Neurosci., 30: 5242-52.
Musiek ES, Milne GL, McLaughlin B, Morrow, JD (2005) Cyclopentenone eicosanoids as mediators of neurodegeneration: A conserved pathogenic mechanism of oxidative stress- and cyclooxygenase-mediated neurotoxicity, Brain Pathol., 15; 149-158.
Yang L, Calingasan NY, Thomas B, Chaturvedi RK, Kiaei M, Wille EJ, Liby KT, Williams C, Royce D, Risingsong R,Musiek ES, Morrow JD, Sporn M, Beal MF (2009) Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PLoS One, 1;4(6):e5757.
© 2006-2012 Washington University School of Medicine